Newsmeme!
Discover News you didn't know existed
DUBLIN----Research and Markets has announced the addition of John Wiley and Sons Ltd's new report "The Biochemistry of Drug Metabolism: Two Volume Set" to their offering.
Ardea Biosciences, Inc. today announced that Felix J. Baker, Ph.D., has been appointed to the Company's Board of Directors. Â Dr. Baker is a managing partner of Baker Bros. Advisors, LLC, the manager and advisor to the funds of Baker Brothers Investments, Ardea's largest shareholder.
Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company’s newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta’s experience in ...
Addex Pharmaceuticals / Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced today that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of ...
Paloma Pharmaceuticals Inc. Posted on:05 Feb 10 JAMAICA PLAIN, Massachusetts, February 4 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD). The Phase I study, "A Phase I Open-Label Study to Investigate the Safety, Tolerability and ...
Biotrial, a key CRO player for early drug development in healthy volunteers and patients, to exhibit at two major life science conferences in February 2010.
BERKELEY HEIGHTS, N.J.----Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company’s newest clinical-stage small molecule.
GENEVA, SWITZERLAND--(Marketwire - February 8, 2010) -
GENEVA, SWITZERLAND--(Marketwire - 02/08/10) - Addex Pharmaceuticals / Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Addex Pharmaceuticals (Swiss: ADXN - News ), the allosteric modulation company, announced today that ADX71943 has demonstrated statistically significant ...
Dr Luo is associate clinical professor in the department of psychiatry of the UCLA Semel Institute for Neuroscience and Human Behavior in Los Angeles. He reports no conflicts of interest concerning the subject matter of this article.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |